Alaproclate

	WikiDoc Resources for Alaproclate
Articles
Most recent articles on Alaproclate Most cited articles on Alaproclate Review articles on Alaproclate Articles on Alaproclate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alaproclate Images of Alaproclate Photos of Alaproclate Podcasts & MP3s on Alaproclate Videos on Alaproclate
Evidence Based Medicine
Cochrane Collaboration on Alaproclate Bandolier on Alaproclate TRIP on Alaproclate
Clinical Trials
Ongoing Trials on Alaproclate at Clinical Trials.gov Trial results on Alaproclate Clinical Trials on Alaproclate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alaproclate NICE Guidance on Alaproclate NHS PRODIGY Guidance FDA on Alaproclate CDC on Alaproclate
Books
Books on Alaproclate
News
Alaproclate in the news Be alerted to news on Alaproclate News trends on Alaproclate
Commentary
Blogs on Alaproclate
Definitions
Definitions of Alaproclate
Patient Resources / Community
Patient resources on Alaproclate Discussion groups on Alaproclate Patient Handouts on Alaproclate Directions to Hospitals Treating Alaproclate Risk calculators and risk factors for Alaproclate
Healthcare Provider Resources
Symptoms of Alaproclate Causes & Risk Factors for Alaproclate Diagnostic studies for Alaproclate Treatment of Alaproclate
Continuing Medical Education (CME)
CME Programs on Alaproclate
International
Alaproclate en Espanol Alaproclate en Francais
Business
Alaproclate in the Marketplace Patents on Alaproclate
Experimental / Informatics
List of terms related to Alaproclate

Alaproclate
Clinical data
Routes of; administration	Oral
ATC code	N06AB07 (WHO) ;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate;
CAS Number	60719-82-6 ; 60719-83-7 (hydrochloride);
PubChem CID	2081;
ChemSpider	1997 ;
UNII	C4R42570ZO;
KEGG	D02787 ;
ChEMBL	ChEMBL36591 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C13H18ClNO2
Molar mass	255.740 g/mol
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(cc1)CC(OC(=O)C(N)C)(C)C;
	InChI InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3 ; Key:FZSPJBYOKQPKCD-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alaproclate (GEA-654) is a psychoactive drug and research chemical that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies. Some studies have found that it acts as a noncompetitive NMDA antagonist, but does not have discriminative stimulus properties similar to phencyclidine.^[1]^[2]

Synthesis

References

↑ Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (December 1994). "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow". The Journal of Pharmacology and Experimental Therapeutics. 271 (3): 1314–9. PMID 7996440. (Subscription required (help)).
↑ Nicholson KL, Balster RL (November 2003). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology (Berlin). 170 (2): 215–24. doi:10.1007/s00213-003-1527-6. PMID 12851738. (Subscription required (help)).
↑ Template:Cite doi

Template:Antidepressants Template:Anxiolytics

[1] Wilkinson A, Courtney M, Westlind-Danielsson A, Hallnemo G, Akerman KE (December 1994). "Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow". The Journal of Pharmacology and Experimental Therapeutics. 271 (3): 1314–9. PMID 7996440. (Subscription required (help)).

[2] Nicholson KL, Balster RL (November 2003). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology (Berlin). 170 (2): 215–24. doi:10.1007/s00213-003-1527-6. PMID 12851738. (Subscription required (help)).

[3] Template:Cite doi

[1]

[2]

[3]

Alaproclate

Overview

Synthesis

See also

References

Navigation menu

Clinical data

Routes of administration	Oral
ATC code	N06AB07 (WHO)
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
CAS Number	60719-82-6^N 60719-83-7 (hydrochloride)
PubChem CID	2081
ChemSpider	1997^Y
UNII	C4R42570ZO
KEGG	D02787^Y
ChEMBL	ChEMBL36591^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₃H₁₈ClNO₂
Molar mass	255.740 g/mol
3D model (JSmol)	Interactive image
SMILES Clc1ccc(cc1)CC(OC(=O)C(N)C)(C)C
InChI InChI=1S/C13H18ClNO2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9H,8,15H2,1-3H3^Y Key:FZSPJBYOKQPKCD-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Alaproclate

Overview

Synthesis

See also

References

Navigation menu

Search